Impact of four sequential measures on the prevention of ventilator-associated pneumonia in cardiac surgery patients by María Pérez-Granda et al.
Pérez-Granda et al. Critical Care 2014, 18:R53
http://ccforum.com/content/18/2/R53RESEARCH Open AccessImpact of four sequential measures on the
prevention of ventilator-associated pneumonia in
cardiac surgery patients
María Jesús Pérez-Granda1,2,5*, José María Barrio1,2, Patricia Muñoz2,3,4,5*, Javier Hortal1,2, Cristina Rincón1
and Emilio Bouza2,3,4Abstract
Introduction: Ventilator-associated pneumonia (VAP) is the most frequent infection in patients admitted to
intensive care units.
The efficacy of individual measures for the prevention of VAP is well documented, and data on the impact of
implementing bundle measures have usually been reported from studies in which several measures are
implemented simultaneously in the general intensive care unit (ICU).
The objective of our work was to evaluate the impact of four sequentially implemented measures for preventing
VAP in a major heart surgery ICU. The measures were a specific training program, aspiration of subglottic secretions
(ASSs), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care
with chlorhexidine.
Methods: We compared rates of VAP, days on mechanical ventilation (MV), and cost of antimicrobial agents
before and during implementation.
Results: We collected data from 401 patients before the intervention and from 1,534 patients during the
intervention. Both groups were comparable. No significant differences in EuroSCORE were observed between
the patients of both periods (6.4 versus 6.3; P = 0.7). The rates of VAP (episodes/1,000 days of ventilation) were,
respectively, 23.9 versus 13.5 (P = 0.005). Mean number of days of MV/1,000 days of stay was 507 versus 375
(P = 0.001), and the cost of antimicrobial therapy (Euros/1,000 days of stay) was €70,612 versus €52,775 (P = 0.10).
The main effect of sequential application of preventive measures in time achieved a relative-rate reduction of
VAP of 41% (IRR, 0.41; 95% CI, 0.28 to 0.62). The mortality rate before and during the intervention was 13.0%
and 10.2%, respectively.
VAP rate was most significantly reduced by training and the use of the inclinometer.
Conclusions: A sequentially applied bundle of four preventive measures reduces VAP rates, days of MV, and
the cost of antimicrobial therapy in patients admitted to the major heart surgery ICU.
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Ventilator-associated pneumonia (VAP) is the most
frequent infection in patients admitted to the intensive
care unit (ICU). It is associated with prolonged hospital
stay [1-3], increased health care costs [4], and an at-
tributable mortality ranging from 8.1% to 31.9% [5-7].
Bundles of preventive measures to reduce the incidence
of VAP usually consist of interventions based on accep-
ted guidelines [4,8,9], which are usually implemented
simultaneously. They are generally evaluated in general
and mixed ICUs, but not in the major heart surgery
ICUs (MHS-ICU) [10].
Our objective was to evaluate the impact of four
sequentially implemented measures to reduce VAP over
a 35-month period in an MHS-ICU. The four measures
were a specific training program, aspiration of subglottic
secretions, introduction of an inclinometer to improve
the semirecumbent position, and reinforcement of oral
care with chlorhexidine.
Material and methods
Hospital setting and patients
Our institution is a general referral hospital with 1,550
beds and approximately 50,000 admissions/year. More
than 500 MHS procedures are performed annually in
the Department of Cardiovascular Surgery, which is a
large referral unit.
Study design
We performed an ecological prospective study with his-
torical controls to analyze MHS patients. We compared
the incidence of VAP before the bundle (9 months) and
during the bundle (35 months).
The first measure was a training program provided by
a panel of experts on VAP in our institution. The program
consisted of eight sessions (15 minutes each) delivered to
all MHS-ICU health care workers.
The second measure was systematic aspiration of
subglottic secretions by using a TaperGuard Evac endo-
tracheal tube (ETT) (Mallinckrodt, USA) over a period
of 13 months. At the time of implementation of this
measure, only these tracheal tubes were available in the
unit to assure compliance. Tracheal aspiration through
the third lumen of the ETT was performed with a nega-
tive pressure of between 100 and 150 mm Hg. Cuff pres-
sure was maintained at between 20 and 30 mm Hg and
monitored during each shift.
The third measure was the incorporation of an inclin-
ometer in the backrest to facilitate the semirecumbent
position. The fourth measure was oral care with chlor-
hexidine, performed every 8 hours and registered every
shift. Compliance with the adequate position and oral care
was measured once a day by a nurse. No other changes in
patient care were included during the study period.Primary end point
The primary end point of the study was the reduction in
the incidence density of VAP.
Secondary end points
The secondary end points were length of ICU stay, days
of MV per ICU stay, mortality rate, cost of antimicrobial
acquisition during ICU stay, and compliance with the
measures.
Ethics
The Ethics Committee of our institution (Hospital Gregorio
Marañon) approved the study and waived the need for
informed consent because we follow the recommendations
of the guidelines for the prevention of ventilator-associated
pneumonia.
Follow-up
Physicians from the Departments of Anesthesia and
Infectious Diseases monitored patients daily to check for
the presence of infections. The infection-control team is
multidisciplinary and comprises physicians and nurses
from the ICU, microbiologists, infectious diseases spe-
cialists, and health care workers from the Preventive
Medicine Department. Data were collected systematic-
ally on a preestablished data form that is routinely used
in the postsurgical MHS-ICU.
Sampling in patients with suspected lower respiratory
tract infection
Sampling of the lower respiratory tract in patients with
suspected VAP was by endotracheal aspiration, protected
specimen brushing, or both. When aspiration was unpro-
ductive, we irrigated with 5 ml of Ringer lactate solution.
Secretions obtained by endotracheal aspiration were collec-
ted in a Lukens specimen container (Sherwood Medical,
Tullamore, Ireland). A sample was considered positive with
bacterial counts ≥104 cfu/ml for each microorganism ob-
tained by using endotracheal aspiration and ≥103 cfu/ml
for each microorganism obtained by using protected speci-
men brushing.
All microorganisms were identified by using standard
methods, and antimicrobial susceptibility was determined
according to Clinical and Laboratory Standards Institute
(CLSI) recommendations.
Demonstration of VAP
Patients ventilated for >48 hours were diagnosed with
VAP based on the presence of new and/or progressive
pulmonary infiltrates on the chest radiograph plus two
or more of the following criteria: fever >38.5°C or hypo-
thermia <36°C, leukocytosis ≥12 × 109/L, purulent tra-
cheobronchial secretions, and a ≥15% reduction in
PaO2/FiO2, according to the definitions of the Centers
Table 1 Baseline characteristics and surgical variables of study patients
Before implementation of bundle During implementation of bundle P value
n = 401 n = 1,534
Preoperative
Mean age in years (SD) 66.45 (12.0) 67.36 (30.6) 0.56
Male sex F/M 162/635 239/897 0.88
Underlying conditions (%)
Myocardial infarction 59 (14.7) 173 (10.4) 0.06
Congestive heart failure 65 (16.2) 217 (14.1) 0.26
Central nervous system disease 18 (4.5) 111 (7.2) 0.05
Chronic obstructive pulmonary disease 71 (17.7) 227 (14.8) 0.15
Renal dysfunction 17 (3.7) 47 (2.82) 0.24
Diabetes mellitus 111 (27.7) 419 (27.3) 0.42
Peptic ulcer disease 11 (2.7) 40 (2.6) 0.88
Peripheral vascular disease 30 (7.5) 118 (7.7) 0.88
Euroscore (±SD) 7.30 (3.33) 6.86 (3.83) 0.93
Severe pulmonary hypertension (%) 60 (15.0) 217 (14.1) 0.67
Type of surgery (%)
Valve replacement 190 (47.4) 696 (45.4) 0.47
CABG 89 (22.2) 362 ( 23.6) 0.55
Mixed (valve and CABG) 58 (14.5) 191 (12.5) 0.28
Aortic surgery 25 (6.2) 114 (7.4) 0.97
Operative data
Mean CPBT (min) (SD) 115.2 (64.0) 118.1 (67.6) 0.92
Mean aortic cross-clamp time (min) (SD) 70.5 (35.0) 76.6 (37.6) 0.18
Intraaortic balloon during the surgery 49 (12.2) 164 (10.7) 0.38
Figure 1 Incidence density of VAP during the study period.
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http://ccforum.com/content/18/2/R53for Disease Control and Prevention [11]. Patients with a
clinical pulmonary infection score (CPIS) higher than 6
were also considered to have pneumonia [12]. The iso-
lation of one or more pathogenic microorganisms in
significant bacterial counts was required to confirm the
diagnosis of VAP.
Unless other evidence was available, we considered as
nonpathogenic the isolation (at any concentration) of
the following microorganisms in lower respiratory secre-
tions: viridans-group streptococci, coagulase-negative
staphylococci, Neisseria spp, Corynebacterium spp, and
Candida spp.
Diagnosis practices did not change after training, and no
surveillance cultures were regularly performed in the unit.
Statistical analysis
Relations between baseline variables were evaluated
before and during implementation of the different pre-
ventive measures. Baseline comparisons between groups
were established by clinical relevance. The qualitative
variables appear with their frequency distribution. The
quantitative variables are summarized as the mean andstandard deviation (SD) or median with IQR, if neces-
sary. Continuous variables were compared by using
the t test for normally distributed variables or median
test for nonnormally distributed variables. The χ2 or
Fisher Exact test was used to compare categoric variables.














Pts: 401 Pts: 453 Pts: 545 Pts: 294 Pts: 242 Pts: 1,534
Median length of ICU stay in days (IQR) 4 (2-7) 5 (3-7) 4 (3-6.5) 4 (2-7) 4 (3-6) 4 (3-7) 0.47
Median days on MV (IQR) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 0.37
Mean days on VM (SD) 4.1 (11.9) 2.7 (5.7) 3.1 (8.9) 2.4 (4.6) 3.1 (9.1) 2.8 (7.4) 0.05
VAP/1,000 days of MV 23.9 14.8 17.8 4.8 10.9 13.5 0.005
Mean days of MV/1,000 days of stay (SD) 507 (128) 412 (103) 359 (85) 342 (99) 390 (77) 375 (93) 0.001
Primary cost of antimicrobial/1,000 days of stay €70,612 €94,839 €39,564 €30,153 €34,671 €52,775 0.10
Mortality (%) 52 (13.0) 56 (10.4) 56 (10.3) 21 (7.1) 23 (9.5) 156 (10.2) 0.10
MV, mechanical ventilation, Pts, patients.
Table 3 Distribution of microorganisms isolated in the
episodes of ventilator-associated pneumonia before and
during the bundle











Enterobacteriaceae 18 33 0.54
Pseudomonas aeruginosa 15 19 0.52




Haemophilus influenzae 2 1 0.55
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(pneumonia) (event/1,000 days of MV), the antimicro-
bial cost, and the days of mechanical ventilation were
compared before and during the interventions. To
evaluate the impact of sequential measures, we per-
formed a time-series analysis with a nonsegmented
Poisson regression test. The change in the temporal
trend was expressed as incidence rate ratio (IRR) and
95% confidence interval (CI) for the whole model and
for each sequential measure. The IRR expresses the
accumulative effect of each intervention implemented
so far.
The slopes for days of mechanical ventilation, days of
ICU stay, and cost of antimicrobial agents were calculated
with a lineal regression model.
All statistical tests were two-tailed. Statistical signifi-
cance was set at P < 0.05 for all the tests. The statistical
analysis was performed with SPSS 12.0 and Stata 11.0.
Results
We compared the results obtained before the interven-
tions (November 2008 to July 2009) and during the inter-
ventions (August 2009 to June 2012).
The underlying conditions and characteristics of the
populations included before and after the interventions
are compared in Table 1. No significant differences in the
underlying conditions and situation of the populations in
either period were detected, and both groups were
comparable.
Type of surgery, mean time on cardiopulmonary by-
pass, aortic cross-clamp time, and other data obtained
during surgery were similar (Table 1).
Primary end point: incidence of VAP
The rates of VAP before and during the intervention
were 23.92/1,000 days and 13.49 episodes/1,000 days of
MV, respectively (P = 0.005) (Figure 1 and Table 2). To
check the stability of the preintervention figures, we
obtained data from January 2007. The incidence density ofVAP in the MHS-ICU during that period was 22.94
episodes/1,000 days of MV. We did not observe any
significant differences in the proportion of etiologic
agents of VAP between the two periods (Table 3).
The accumulated monthly effect of each intervention
individually and as a bundle is showed in Table 4.
The IRR of VAP decreased by 51% after the imple-
mentation of the training program (IRR, 0.51; 95% CI,
0.34 to 0.78) and after the introduction of the first three
measures, VAP decreased another monthly 45% (IRR, 0.45;
95% CI, 0.24 to.84).
Secondary end points
Cost of antimicrobial acquisition during ICU stay
The cost of acquisition of antibiotics fell between the
two periods (€70,612/1,000 days of ICU stay versus
€52,775/1,000 days of ICU stay; P = 0.10) (Table 2).
Table 4 and Figure 2 show the accumulated monthly
effect of each intervention in antimicrobial cost.
Table 4 Time-series analysis of the accumulated monthly effect of each intervention individually and of the whole
bundle of measures
Beta 95% CI Beta P
VAP rate* Mean change by month
Full model Before and after training 0.50 0.29 0.84 0.009
Before and after ASS 1.05 0.60 1.85 0.856
Before and after inclinometer 0.26 0.09 0.74 0.011
Before and after oral care 0.02 0.01 0.03 0.117
Final model Before and after training 0.51 0.34 0.78 0.002
Before and after inclinometer 0.45 0.24 0.84 0.013
Bundle 0.41 0.28 0.62 <0.001
Cost of antimicrobial/1,000 days of stay
Full model (Constant) 56,800 29.84 83.77 0.000
Before and after training -2.010 -45.11 41.09 0.925
Before and after ASS -87.040 -133.81 -40.26 0.001
Before and after inclinometer -37.030 -81.77 7.71 0.102
Before and after oral care -12.060 -54.31 30.20 0.567
Monthly change 2.760 -0.58 6.10 0.102
Final model (Constant) 59,110 33.93 84.30 0.000
Before and after ASS -82,600 -122.64 -42.55 0.000
Before and after inclinometer -37,840 -73.79 -1.90 0.040
Monthly change 2,420 0.35 4.50 0.023
Bundle -17,840 -47.59 11.92 0.233
Days of MV/1,000 days of stay
Full model (Constant) 489.47 402.19 576.75 0.000
Before and after training -128.51 -268.02 11.00 0.070
Before and after ASS -93.99 -245.38 57.39 0.216
Before and after inclinometer -51.81 -196.61 92.99 0.473
Before and after oral care 26.75 -110.01 163.52 0.694
Monthly change 3.54 -7.26 14.34 0.511
Final model (Constant) 507.17 439.70 574.65 0.000
Before and after training -131.70 -207.35 -56.04 0.001
Bundle -131.70 -207.35 -56.04 0.001
*Data was expressed as incidence rate ratio by Poisson model.
Cost of antimicrobials
Rate of VAP
Figure 2 Evolution of cost of antimicrobials and VAP rate during study period.
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The mean number of days of MV/1,000 days of stay was
estimated. Mean days of MV/1,000 days of ICU stay
before and after the intervention were, respectively, 507/
1,000 days of stay and 375/1,000 days of stay (P = 0.001)
(Figure 3 and Table 2). The overall reduction in the
mean number of days on MV was 131.70 MV/1,000 days
of stay (95% CI, −207.35 to −56.04) (Table 4). Training
was the only measure with a significant effect on the
days of MV.
Compliance with the measures
The degree of compliance with the education, systematic
aspiration of subglottic secretions, and oral care with
chlorhexidine every 8 hours was 100%. However, it was
lower for the implementation of the ideal semirecum-
bent position to an adequate angle (between 30 degrees
and 45 degrees). It was only slightly modified from one
period to the next with the inclusion of the inclinometer
(mean before, 40.26% versus mean after, 42.05%; P = 0.68).
The mortality rate before and after the intervention
was 13% (52 patients) and 10.2% (156 patients), P = 0.10.
Discussion
The sequential implementation of a bundle of measures
to prevent VAP in patients undergoing MHS reduced
the incidence density of VAP and the days on MV. A
trend was noted to the reduction of the cost of acquisi-
tion of antimicrobial agents.
VAP is the most frequent infection after MHS, with
incidence rates ranging from 5.7% to 21.6% and inci-
dence densities ranging from 22.2/1,000 days of MV to
34.5/1,000 days of MV in all patients undergoing surgery
[2,13-15].
VAP is associated with a high mortality rate, but only
a few predisposing risk factors can be modified [16-18].
Many groups and scientific societies have provided pre-
vention guidelines in the last 10 years [19-22]. SeveralDays of MV
Figure 3 Evolution of MV/1,000 days of ICU stay and VAP rate duringguidelines recommend different measures to decrease
the incidence of VAP, including training, which quickly
reduces the incidence of VAP rates, although its long-
term efficacy is limited [23,24].
Pathogenic mechanism of VAP is mainly by aspir-
ation of secretions with bacteria colonizing the upper
respiratory tract and passing into the lower respira-
tory tract via the leaks between the tracheal wall and
the cuff of the endotracheal tube (ETT). The use of
ETTs with a third lumen that permits aspiration of
subglottic secretions has been associated with a reduction
in VAP rates [25]. Despite being recommended by guide-
lines, this measure is far from being universally imple-
mented in ICUs [2].
A backrest elevation of 30 degrees to 45 degrees is
recommended to decrease the incidence of VAP, although
implementation is influenced by clinical practice and the
patient’s condition, and subjective perception of the angle
of inclination is limited [26-29].
Oral care also plays a role in the prevention of VAP,
although no uniform protocol of application is currently
available [30,31].
Many ICUs cannot implement simultaneously all the
measures included in a bundle. Our study shows that
sequential introduction of preventive techniques have a
global impact in the reduction of VAP, but the design of
our study, with measures that are accumulated additively
to the previous ones, do not permit clearly an estimation
of the impact of simple individual measures.
Our study is limited in that we enrolled only the popu-
lation undergoing MHS; therefore, our data cannot
necessarily be extrapolated to other populations.
Conclusion
Our study shows that the implementation of preventive
measures for VAP are effective, even if the measures
were implemented in the high-risk population for VAP
admitted into Major Heart Surgery ICUs.Rate of VAP 
the period of study.
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 A prevention of VAP in MHS-ICUs is feasible with
the implementation of four simple measures, even
when sequentially implanted.
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